Friday 6 November 2026
Export CHE’s income statement to Excel — free account
Chemed Corporation
CHE Healthcare Medical Care Facilities
Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +23.1%
- Free cash flow
- −45.3%
Quarter to September 2026, against a year earlier
525.70
8.07
−1.51%
Follow CHE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.19 | 20.54 | 23.37 | 24.10 |
P/S ratio |
2.43 | 2.03 | 2.36 | 2.48 | |
P/FCF ratio |
18.67 | 13.53 | 18.70 | 22.22 | |
P/Operating CF |
46.13 | 58.55 | 72.34 | 116.54 | |
P/B ratio |
6.29 | 6.09 | 7.39 | 7.66 | |
Price to Tangible BV |
26.83 | 64.51 | 116.84 | 236.62 | |
EV/Sales |
2.45 | 2.06 | 2.40 | 2.55 | |
EV/EBITDA |
15.34 | 13.31 | 15.00 | 15.47 | |
EV/Operating CF |
15.94 | 11.82 | 16.00 | 18.69 | |
EV/FCF |
18.75 | 13.74 | 19.02 | 22.87 | |
Quick Ratio |
0.90 | 0.72 | 0.72 | 0.92 | |
Current Ratio |
1.05 | 0.85 | 0.91 | 1.11 | |
Net Debt/EBITDA |
(0.64) | 0.73 | 0.94 | 1.65 | |
Debt/Assets |
0.00% | 5.94% | 8.86% | 13.73% | |
Debt/Equity |
0.00 | 0.11 | 0.17 | 0.27 | |
Asset Turnover |
1.58 | 1.56 | 1.57 | 1.59 | |
Operating CF/Net income |
1.74 | 1.33 | 1.25 | 0.79 | |
Capex/Depreciation |
(0.95) | (1.00) | (0.89) | (1.07) | |
Interest Coverage |
193.19 | 165.19 | 49.86 | 45.98 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.50% | 17.39% | 17.11% | 16.13% | |
Intangible Assets out of Total Assets |
0.49 | 0.50 | 0.49 | 0.49 | |
Share Based Compensation of Revenue |
1.58% | 1.62% | 1.68% | 1.32% | |
Graham Net Nets |
(0.04) | (0.08) | (0.07) | (0.07) | |
Graham Number |
168.04 | 160.18 | 168.14 | 176.38 | |
Earnings Yield |
4.31% | 4.87% | 4.28% | 4.15% | |
Free Cash Flow Yield |
5.36% | 7.39% | 5.35% | 4.50% | |
Revenue per Share |
44.40 | 48.08 | 51.10 | 52.91 | |
Operating CF per Share |
9.27 | 6.45 | 6.44 | 4.33 | |
Capex per Share |
(1.08) | (1.24) | (1.16) | (1.43) | |
Free Cash Flow per Share |
8.20 | 5.21 | 5.28 | 2.91 | |
Cash per Share |
5.18 | 1.23 | 3.05 | 3.71 | |
Shareholders Equity per Share |
68.02 | 62.01 | 63.04 | 65.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
68.02 | 62.01 | 63.04 | 65.97 | |
Free Cash Flow |
118.00 | 71.24 | 69.58 | 37.94 | |
Working Capital |
15.49 | (47.35) | (28.61) | 34.79 | |
Capital Expenditures |
(15.53) | (16.98) | (15.23) | (18.65) | |
Net Current Asset Value |
(256.17) | (413.76) | (457.84) | (491.29) | |
EV/EBIT |
18.30 | 15.99 | 17.87 | 18.30 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.03 | |
Price to Operating Income |
18.21 | 15.75 | 17.57 | 17.78 | |
| Other line items | |||||
Average Receivables |
176.87 | 250.68 | 186.76 | 235.22 | |
Average Payables |
54.30 | 56.70 | 67.79 | 56.70 | |
Average Inventory |
7.87 | 7.50 | 8.39 | 7.99 | |
Average Assets |
1,603.38 | 1,631.17 | 1,648.72 | 1,671.03 | |
Average Common Equity |
1,049.20 | 1,014.88 | 1,014.50 | 969.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026